Elicio Therapeutics Inc./$ELTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Ticker
$ELTX
Sector
Primary listing
Employees
33
Headquarters
Website
ELTX Metrics
BasicAdvanced
$196M
-
-$2.58
1.68
-
Price and volume
Market cap
$196M
Beta
1.68
52-week high
$14.93
52-week low
$4.60
Average daily volume
142K
Financial strength
Current ratio
2.381
Quick ratio
2.289
Long term debt to equity
985.086
Total debt to equity
985.086
Interest coverage (TTM)
-33.29%
Profitability
EBITDA (TTM)
-37.51
Management effectiveness
Return on assets (TTM)
-87.24%
Return on equity (TTM)
817.92%
Valuation
Price to book
115.99
Price to tangible book (TTM)
115.99
Price to free cash flow (TTM)
-4.416
Free cash flow yield (TTM)
-22.65%
Free cash flow per share (TTM)
-2.414
Growth
Earnings per share change (TTM)
-39.24%
3-year earnings per share growth (CAGR)
-69.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Elicio Therapeutics Inc. stock?
Elicio Therapeutics Inc. (ELTX) has a market cap of $196M as of April 03, 2026.
What is the P/E ratio for Elicio Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Elicio Therapeutics Inc. (ELTX) stock is 0 as of April 03, 2026.
Does Elicio Therapeutics Inc. stock pay dividends?
No, Elicio Therapeutics Inc. (ELTX) stock does not pay dividends to its shareholders as of April 03, 2026.
When is the next Elicio Therapeutics Inc. dividend payment date?
Elicio Therapeutics Inc. (ELTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Elicio Therapeutics Inc.?
Elicio Therapeutics Inc. (ELTX) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.